Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 222-048-3 | CAS number: 3327-22-8
The key oral study, conducted in a manner similar to (the now deleted) OECD 401 involved gavage administration of one of five doses of a 60% solution of CHPTAC to male and female rats. An LD50 value of 3.2 mL/kg bw was reported (equivalent to 3688 mg/kg bw, or 2213 mg/kg bw for pure CHPTAC).
The key dermal study, conducted according to OECD 402, involved 24-h occluded contact with the test material (65% aqueous CHPTAC). An LD50 value in rats greater than 2348 mg/kg bw was derived for the test material, that has been said to equate to 1526 mg/kg bw for 100% CHPTAC.
No suitable data are available for the inhalation route.
Table 1: Mortality
Death occurred within 1 h of dosing; survivors recovered and there were no overt signs of toxicity. No gross abnormalities were identified on examination.
LD50 (Servon XRK 60) = 3.20 mL/kg bw. or 3.68 g/kg bw (TS specific gravity 1.15)
Equivalent to an LD50 for 100% CHPTAC of 2213 mg/kg bw/day
In an acute toxicity study, the toxic potential of CHPTAC was tested dermally on male and female rats. A LD 50 value for 60% CHPTAC of 3.20 mL/kg bw was identified in male and female rats. This would be equivalent to an LD50 for 100% CHPTAC of 2213 mg/kg bw.
A limit test was conducted to assess the dermal toxicity of the test substance (65% CHPTAC). Under the experimental conditions the dermal LD50 value was found to be greater than 2348 mg/kg which corresponds to 1526 mg/kg of pure CHPTAC.
The key oral study was chosen from 4 studies of reliability 2 (reliable with restrictions) as the most recent of those for which sufficient data were available for review during entry to IUCLID5. Findings from the remaining three studies supported those of the key study. Where adequate data were available the LD50 values for pure CHPTAC were in every case greater than 2000 mg/kg bw/day. For a further two studies (reliability 4) an LD50 of >2000 mg/kg bw/day was also given, apparently in relation to an aqueous solution of CHPTAC, giving a conversion to an LD50 lower than 2000 mg/kg bw/day for the pure substance. However, sufficient details were not available during entry to IUCLID5 for this to be reliably ascertained.
The study selected by FIN to provide the LD50 used in risk characterization (Kynoch et al., 1982/Dynamit Nobel, 1982) was not available during entry to IUCLID5. The LD50 value identified in this study is very similar to that of the key study.
The key dermal study was chosen from two very similar studies in the rat. The findings of the supporting study confirm those of the key study.
Based on the available data, classification via the oral route is not required (Regulation (EC) No 1272/2008; Directive 67/548/EEC).
The studies identified do not indicate classification via the dermal route for the test material (Regulation (EC) No. 1272/2008; Directive 67/548/EEC). However, conversion to account for the concentration of CHPTAC in the test material means that the tested dose of pure CHPTAC was slightly lower than the upper value (2000 mg/kg bw) above which classification would not be required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again